Stereotaxis, Inc.
As of Oct 22, 2026, Stereotaxis is in Stage 4, the downtrend phase, now in week 17 (since Jun 25, 2026). It closed at $1.00, 67.7% below its 52-week high and below its 200-day average, which is falling.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is STXS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
STXS among Medical Instruments & Supplies42nd of 51 by relative strength
All 51 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | PLSE | Stage 2 · wk 34 | 98 | +1.3% |
| 2 | PDEX | Stage 2 · wk 36 | 97 | −13.3% |
| 3 | HBIO | Stage 2 · wk 11 | 95 | +3.6% |
| 4 | ATRC | Stage 2 · wk 10 | 89 | −1.1% |
| 5 | WST | Stage 2 · wk 24 | 82 | +4.8% |
| 6 | BDX | Stage 2 · wk 11 | 81 | +9.8% |
| 7 | ICUI | Stage 3 · wk 1 | 81 | +3.1% |
| 8 | OSUR | Stage 3 · wk 8 | 75 | −4.8% |
| …42 | STXS | Stage 4 · wk 17 | 16 | −24.2% |
Stereotaxis: quick answers
What stage is Stereotaxis in?
As of Oct 22, 2026, Stereotaxis (STXS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 25, 2026 and is in week 17. What the four stages mean
Is Stereotaxis in an uptrend?
No. Stereotaxis is in a Stage 4 downtrend. It trades 43.1% below its 200-day average, which is falling.
How far is Stereotaxis from its 52-week high?
Stereotaxis closed at $1.00 on Oct 22, 2026, 67.7% below its 52-week high of $3.10. Its 52-week low is $0.99.
How has Stereotaxis performed over the past year?
As of Oct 22, 2026, Stereotaxis is down 67.2% over the past year and down 56.9% so far in 2026.
Which sector and industry is Stereotaxis in?
Stereotaxis is in the Medical Instruments & Supplies industry, part of the Health Care sector.
About this companyHealth Care· Medical Instruments & Supplies
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.